PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
184.59
P/E exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.85. Michael Burry would check for market euphoria. Scrutinize growth expectations.
714.09
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.85. Jim Chanos would check for potential multiple compression risks.
19.29
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.51. Jim Chanos would check for potential asset write-down risks.
-178.11
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -13.09. Seth Klarman would investigate cash flow improvement potential.
1169.56
P/OCF of 1169.56 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
19.29
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.50. Jim Chanos would check for valuation bubble risks.
0.14%
Earnings yield exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.08%. Joel Greenblatt would investigate if high yield reflects hidden value.
-0.56%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.05%. Seth Klarman would investigate cash flow improvement potential.